Actualités

ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.

AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal worth about $10.9

SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.

AbbVie announced Monday a $10.9 billion plan to acquire immunology-focused Apogee Therapeutics, sending Apogee stock flying.

U.S. stock futures edged higher on Monday as investors monitored corporate dealmaking activity and developments in the biotechnology and cryptocurrency sectors.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

AbbVie (NYSE:ABBV) announced on Monday that it has agreed to acquire Apogee Therapeutics (NASDAQ:APGE) for $10. 9 billion, marking its largest acquisition in more than five years and reinforcing its commitment to expanding its next-generation immunology pipeline.

US futures were pointing higher at the start of the week as investors return from the Juneteenth holiday weekend, with technology stocks expected to lead gains despite lingering uncertainty over the Middle East and the prospect of further Federal Reserve tightening. Dow Jones futures were up...

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis

AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.

AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company’s immunology and inflammation portfolio.

June 22 (Reuters) - AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline.

↘️ SpaceX (SPCX): Shares of Elon Musk's rocket company declined 3% premarket, setting up the stock for its third straight session of declines since it began trading publicly a little over a week ago. ↗️ Intel (INTC): Shares in the tech giant climbed 4% premarket.

AbbVie Inc. (NYSE:ABBV) is one of the 12 High Quality Stocks to Buy for the Long Term. On June 16, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced the U.S. FDA approval of Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults over the age of 21. AbbVie said Skinvive […]

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Don't wait too long to get in on these outstanding dividend payers.

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18, a steep markup ...

Ten thousand dollars a month works out to $120,000 a year, an income stream that exceeds the roughly $68,359 in per-capita disposable personal income reported by the Bureau of Economic Analysis for the first quarter of 2026. For many retirees, that level of cash flow would support a lifestyle well above basic needs. The real ... The Retirement Portfolio That Forks Over a $10,000 Check Every Month

(Bloomberg) -- Global stocks are ending a strong week on a cautious note as relief over an interim peace deal between the US and Iran gave way to a focus on the significant hurdles that remain to secure a lasting agreement.Most Read from BloombergRead the 14-Point Draft Memorandum Between the US and IranModi Warns of ‘Shortage of Trust’ Ahead of Trump MeetingTrump Blows Through His Iran Red Lines in Justifying Peace DealUS and Iran Delay Nuclear Talks as Lebanon Clashes WorsenUS Tells ASML It’s

While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.

The US Food and Drug Administration said Thursday it is requesting updates to prescribing informatio

In the most recent trading session, AbbVie (ABBV) closed at $216.49, indicating a -2.14% shift from the previous trading day.

The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.

AbbVie (NYSE:ABBV) reported positive Phase 3 results for a venetoclax-based combination in untreated chronic lymphocytic leukemia in less-fit patients. The company also received U.S. FDA approval for SKINVIVE by JUVÉDERM for reducing neck lines and improving neck appearance. AbbVie operates at the intersection of large-scale pharmaceuticals and medical aesthetics, with products that span immunology, oncology, neuroscience and cosmetic treatments. The latest data in chronic lymphocytic...

Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.

AbbVie Inc. (NYSE:ABBV) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, AbbVie Inc. (NYSE:ABBV) announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association 2026 Congress in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic […]

The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.

Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.